Enhancing NeuroD1 Expression to Convert Lineage-Traced Astrocytes into Neurons

share:

Brief intro:

  • Author: Liang Xu, Zong-Qin Xiang, Yao-Wei Guo, Yu-Ge Xu, Min-Hui Liu, Wen-Yu Ji, Shu He, Wen-Liang Lei, Wen Li, Zheng Wu and Gong Chen
  • Journal: BioRxiv
  • Doi: https://www.doi.org/10.1101/2022.06.21.496971
  • Publication Date: 2022 Jun 2

Products/Services used in the paper

Quotation shows PackGene:Recombinant AAV5 and AAV9 Adeno-associated virus were produced by PackGene® Biotech, LLC, purified through iodixanol gradient ultracentrifuge and subsequent concentration.

Research Field:CNS

AAV Serotype:AAV5 and AAV9

Targeted organ:brain

Animal or cell line strain:Brain surgeries were performed on 4-8 weeks old wild-type mice for viral injection.

Request Quote

Abstract

Regenerating functional new neurons in adult mammalian brains has been proven a difficult task for decades. Recent advancement in direct glia-to-neuron conversion in vivo opens a new field for neural regeneration and repair. However, this emerging new field is facing serious challenges from misuse of viral vectors to misinterpretation of conversion data. Here, we employ a variety of AAV vectors with different promoters and enhancers to demonstrate that astrocytes can be converted into neurons in a NeuroD1 dose-dependent manner in both wildtype (WT) and transgenic mice. Notably, astrocytes in WT mice were relatively easy to convert with higher conversion efficiency, whereas lineage-traced astrocytes in Aldh1l1-CreERT2 mice showed high resistance to reprogramming but were still converted into neurons after enhancing NeuroD1 expression with CMV enhancer. Furthermore, under two-photon microscope, we observed direct astrocyte-to-neuron conversion within 3 weeks of serial live imaging in the mouse cortex. We also demonstrated that high titre AAV reaching 1013 GC/ml caused severe neuronal leakage using a variety of AAV GFAP::GFP vectors, highlighting the necessity to inject low titre AAV into healthy brains to avoid artifactual results. Together, our studies suggest that lineage-traced astrocytes can be converted into neurons but require stronger conversion force such as enhanced NeuroD1 expression. Failure to recognize the difference between WT astrocytes and lineage-traced astrocytes in terms of conversion barrier will lead to misinterpretation of data.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download